Agranulocitosis secundaria a clozapina: un estudio descriptivo en pacientes chilenos

摘要

Introduction: Agranulocytosis is one of the most serious adverse effects of clozapine. The Latin American literature is currently scarce on the subject. Objective: To describe the occurrence ofagranulocytosis or leukopenia secondary to clozapine and its associated factors in a sample ofChilean patients between the years 2011-2016. Materials and Methods: An observational,retrospective type of study was designed base on virtual information from the NationalPharmacovigilance Registry and definition of alarm levels according to the Technical Standardof clozapine, later performing statistical analysis. Results: total n 60 patients, 8 patients withsome alarm event; Alarm 1:5; Alarm II: 1; Alarm III: 2. Alarms were distributed between week1 and week 242. The incidence was higher between weeks 0 and 12 (1.26%). Until week 18,53%of alarms I and 100% of alarms III occurred, alarm II occurred in month 10. Discussion: Whencomparing patients with and without alarm, significant differences were found in the basalcount of leukocytes and neutrophils, with no differences in age and sex. Patients who presentedalarms and/or lower baseline leukocyte or neutrophil counts could eventually benefit from alonger weekly follow-up. Conclusion: This study constitutes the first step towards exploring theadverse effects profile of clozapine in Chilean patients.